Skip to content
DataLookout
Menu

NCT07254793

Prophylactic DLI-X for Leukemia Relapse After HCT

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Nov 30, 2026 to Oct 26, 2026
    • Site details revised
  2. Notable Enrollment increased: 94 → 180 participants Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Start date: Oct 31, 2026 to Nov 30, 2026
    • Eligibility criteria shortened, about 14 words
    • Interventions modified
    • Study title shortened, about 2 words
  3. Notable Start date: May 31, 2026 to Oct 31, 2026v3
  4. Notable Start date: Feb 28, 2026 to May 31, 2026v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Prophylactic endpoint: Graft-versus-Host Disease-Free, Relapse-Free Survival (GRFS)
Timeframe: Assess between 1 to 3 years post HCT

Arms and interventions

Prophylactic DLI-X ArmExperimental

Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive pro-DLI-X.

Prophylactic Standard DLI ArmActive comparator

Conduct the first-in-human, randomized clinical trial comparing prophylactic exercise mobilized donor lymphocyte infusion (pro-DLI-X) with standard (non exercise mobilized) prophylactic DLI (pro-DLI) for relapse prevention following allogeneic hematopoietic cell transplantation (alloHCT) in patients with myeloid or lymphoid malignancies. Patients on this arm will receive standard DLI-X.

Biologicals: Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI

Sites

1 site in 1 country

  • The University of Arizona Cancer CenterTucson, Arizona, United States